Over a period of time, the cancer research has deviated for conventional approach and is directed towards the development of novel drugs that selectively targets the oncogenes, thereby reducing the adverse side effects. Genomic analysis have shown that B-cell maturation antigen or CD269 is restrictively expressed in both normal as well as malignant cells at high levels, thus making it an ideal target antigen for development of novel multiple myeloma therapies. BCMA is a member of tumor necrosis factor family and has critical role in the regulating B-cell proliferation and survival.
Ghurry.com is a 100% free social bookmarking website where you could add your content. Users can publish their blogging articles, business articles, corporate news, travel news, food news, entertainment news, and services they offer.